Brief: Spyglass Pharma Announces Positive 4-Year Data From First-In-Human Trial Of BIM-Iol System
Mon 13:58
BRIEF-Spyglass Pharma Announces Positive 4-Year Data From First-In-Human Trial Of BIM-Iol System Oct 19 (Reuters) - SpyGlass Pharma, Inc. SGP.O:
ANNOUNCES POSITIVE 4-YEAR DATA FROM FIRST-IN-HUMAN TRIAL OF ITS INNOVATIVE BIM-IOL SYSTEM
REPORTS 37% REDUCTION IN MEAN INTRAOCULAR PRESSURE AT 4-YEAR TIMEPOINT
ANNOUNCES POSITIVE 4-YEAR TRIAL RESULTS FOR BIM-IOL SYSTEM
NO PRODUCT-RELATED ADVERSE EVENTS REPORTED AT 4-YEAR TIMEPOINT
90% OF PATIENTS MAINTAINED ≥20/25 VISUAL ACUITY AT 4-YEAR TIMEPOINT
REPORTS INTERIM SAFETY AND EFFICACY DATA FOR 21 PATIENTS AT 4-YEAR TIMEPOINT
Source text: ID:nGNX3k9CTb
Further company coverage: SGP.O
((Reutersbriefs@thomsonreuters.com;))
Recent news on SpyGlass Pharma
See all newsBrief: Spyglass Pharma Announces Positive 4-Year Data From First-In-Human Trial Of BIM-Iol System
SpyGlass Pharma Q2 net loss widens on higher expenses
Brief: Spyglass Pharma Inc - BIM-Iol System Phase 3 Trial Enrollment Expected To Complete In 2027
Flagship-backed Generate Biomedicines eyes $2.2 billion valuation in US IPO (updated)
NASDAQ RESUMED AT 01:46 PM